Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Expert Opinion on Investigational Drugs|January 30, 2016
Integrin antagonists as potential therapeutic options for the treatment of Crohn's diseaseLeon P McLean, Raymond K CrossExpert Opinion on Drug Metabolism & Toxicology|April 21, 2016
Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitisLeon P McLean, Raymond K CrossExpert Review of Gastroenterology & Hepatology|February 5, 2014
Adverse events in IBD: to stop or continue immune suppressant and biologic treatmentLeon P McLean, Raymond K CrossImmunotherapy|September 4, 2013
Combined blockade of IL-17A and IL-17F may prevent the development of experimental colitisLeon P McLean, Raymond K Cross, Terez Shea-DonohueImmunotherapy|October 11, 2012
Vedolizumab for the treatment of ulcerative colitis and Crohn's diseaseLeon P McLean, Terez Shea-Donohue, Raymond K CrossExpert Review of Gastroenterology & Hepatology|February 23, 2019
Adverse events in IBD therapy: the 2018 updateSandra M Quezada, Leon P McLean, Raymond K CrossPharmacotherapy|August 30, 2008
Diabetic ketoacidosis associated with aripiprazoleZaineb H Makhzoumi, Leon P McLean, Jefferson H Lee, et al.Cytokine|July 20, 2015
Enteric nematodes and the path to up-regulation of type 2 cytokines IL-4 and IL-13Terez Shea-Donohue, Rex Sun, Jennifer A Bohl, et al.Clinical Colorectal Cancer|February 6, 2018
Frequency of Surveillance and Impact of Surveillance Colonoscopies in Patients With Ulcerative Colitis Who Developed Colorectal CancerElisabeth B Cole, Yash Shah, Leon P McLean, et al.American Journal of Physiology. Gastrointestinal and Liver Physiology|May 14, 2016
Type 3 muscarinic receptors contribute to intestinal mucosal homeostasis and clearance of Nippostrongylus brasiliensis through induction of TH2 cytokinesLeon P McLean, Allen Smith, Lumei Cheung, et al.Pageof 2